Učitavanje...
Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
BACKGROUND/AIMS: Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether TLI or ATI better correlates with LOR (Study 1), and whether TLI could becom...
Spremljeno u:
| Izdano u: | Intest Res |
|---|---|
| Glavni autori: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Korean Association for the Study of Intestinal Diseases
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5934595/ https://ncbi.nlm.nih.gov/pubmed/29743835 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2018.16.2.223 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|